Safety Profile of Peptide YY

Evidence Limitation: The available evidence provides very limited information specifically about the safety profile of peptide YY (PYY) as a therapeutic compound. Most of the provided studies focus on endogenous PYY levels in various populations or dietary interventions that affect PYY, rather than direct administration of PYY as a treatment.

Known Side Effects

The evidence provided does not contain specific information about side effects from PYY administration. One clinical trial (NCT01515319) was identified as a "Safety and Pharmacokinetic Study of Y242" in adult subjects, but the results and safety findings are not included in the available evidence.

Contraindications

No specific contraindications for PYY therapy are documented in the provided evidence.

Drug Interactions

The available evidence does not provide information about drug interactions with PYY.

Populations That Should Avoid PYY

Based on the limited evidence provided:

Pregnant and breastfeeding women: No safety data is available for these populations
Children: While some studies examined PYY levels in children with metabolic diseases, no safety data for PYY administration in pediatric populations is provided
Patients with specific medical conditions: The evidence does not specify which medical conditions might contraindicate PYY use

Research Gaps

The evidence base for PYY safety is notably thin. While several studies examine endogenous PYY levels and responses to dietary interventions, there is insufficient published safety data from clinical trials involving direct PYY administration. The completed Phase 1 safety study mentioned (NCT01515319) could potentially provide relevant safety information, but the results are not included in the available evidence.

Medical Disclaimer: This information is for educational purposes only and should not be used for medical decision-making. Patients considering any PYY-based therapy should consult with their healthcare provider to discuss potential risks, benefits, and individual considerations.

Peptide YY